Recent advances in drug-induced angioedema

Allergology International

Volumn 61, Issue 4, 2012, Pages 545-557

  Inomata, Naoko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Angioedema; Angiotensin converting enzyme inhibitor; Bradykinin; Non steroidal anti inflammatory drugs; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ALTEPLASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIALLERGIC AGENT; ANTISERUM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETORICOXIB; FLUOXETINE; GLUCOCORTICOID; ICATIBANT; IODINATED CONTRAST MEDIUM; LARONIDASE; LEPIRUDIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PENICILLIN DERIVATIVE; PYRAZOLONE DERIVATIVE; QUINOLONE DERIVATIVE; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC URTICARIA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG CROSS TOLERANCE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FOOD ALLERGY; HUMAN; HYPERTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; JAPANESE; KIDNEY DYSFUNCTION; LARYNX EDEMA; MEDICAL HISTORY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; RISK FACTOR; SKIN MANIFESTATION; URTICARIA;

EID: 84871503795     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.12-RAI-0493     Document Type: Review

References (82)

1. Hide M, Morita E, Furukawa F et al. [Guidelines for urticaria and angioedema.] [Jpn J Dermatol] 2011;121:1339-88 (in Japanese).
2. Greaves MW, Lawlor F. Angioedema: Manifestations and management. J AmAcad Dermatol 1991;25:155-65.
3. Sánchez-Borges M, González-Aveledo LA. Angiotensinconverting enzyme inhibitors and angioedema. Allergy Asthma Immunol Res 2010;2:195-8.
4. Lerch M. Drug-induced angioedema. Chem Immunol Allergy 2012;97:98-105.
5. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005;53:373-88.
6. Iwamoto K, Mihara S, Ikezawa Z, Hide M. [National prevalence survey of hereditary angioedema in Japan]. Arerugi 2011;60:26-32 (in Japanese).
7. Antúnez C, Martín E, Cornejo-García JA et al. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des 2006;12:3327-33.
8. Bas M, Kojda G, Bier H, Hoffmann TK. [ACE inhibitorinduced angioedema in the head and neck region. A matter of time?] HNO 2004;52:886-90 (in German).
9. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001;24:599-606.
10. Zingale LC, Beltrami L, Zanichelli A et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006;175:1065-70.
11. Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994;106:1922-3.
12. Sauvé L, Gras-Champel V, Decocq G et al. [Angioedema associated with the use of dihydropyridines.]. Therapie 1999;54:64-5 (in French).
13. Burches E, Garcia-Verdegay F, Ferrer M, Pelaez A. Amiodarone-induced angioedema. Allergy 2000;55:1199-200.
14. Cooney C, Nagy A. Angio-oedema associated with risperidone. BMJ 1995;311:1204.
15. Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling. J Clin Psychiatry 1996;57:486.
16. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1996;60:714-25.
17. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177-80.
18. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980;35:149-54.
19. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E, Reed CE, Ellis EF et al (eds). Allergy: Principles and Practice, 5th edn. St Louis: CV Mosby, 1998;1225-34.
20. Tan EK, Grattan CE. Drug-induced urticarial. Expert Opin Drug Saf 2004;3:471-84.
21. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-21.
22. Stevenson DD, Mathison DA. Aspirin sensitivity in asthmatics. When may this drug be safe? Postgrad Med 1985;78:111-3, 116-9.
23. Kong JS, Teuber SS, Gershwin ME. Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity. Clin Rev Allergy Immunol 2007;32:97-110.
24. Inomata N, Osuna H, Yamaguchi J et al. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. J Dermatol 2007;34:172-7.
25. Harada S, Horikawa T, Ashida M et al. Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol 2001;145:336-9.
26. Settipane GA. Aspirin sensitivity and allergy. Biomed Pharmacother 1988;42:493-8.
27. Doña I, Blanca-López N, Jagemann LR et al. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy 2011;66:1428-33.
28. Kim SH, Ye YM, Lee SK, Park HS. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol 2006;6:266-70.
29. Grzelewska-Rzymowska I, Szmidt M, Rozniecki J. Aspirininduced urticaria-a clinical study. J Investig Allergol Clin Immunol 1992;2:39-42.
30. Blanca M, Perez E, Garcia JJ et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989;62:295-8.
31. Asero R. Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria /angioedema: update. Allergy Asthma Clin Immunol 2007;3:24-30.
32. Kubota Y, Imayama S, Toshitani A et al. Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 1997;114:361-6.
33. May A, Weber A, Gall H, Kaufmann R, Zollner TM. Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 1999;29:1402-11.
34. Pérez C, Sánchez-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001;108:1060-1.
35. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A doubleblind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001;31:1607-14.
36. Ohnishi-Inoue Y, Mitsuya K, Horio T. Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. Br J Dermatol 1998;138:483-5.
37. Prieto A, De Barrio M, Martín E et al. Tolerability to nabumetone and meloxicamin patients with nonsteroidal antiinflammatory drug intolerance. J Allergy Clin Immunol 2007;119:960-4.
38. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773-86.
39. Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577-82.
40. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory druginduced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154-8.
41. Viola M, Quaratino D, Volpetti S et al. Parecoxib tolerability in patients with hypersensitivity to nonsteroidal antiinflammatory drugs. J Allergy Clin Immunol 2006;117:1189-91.
42. Weberschock TB, Müller SM, Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res 2007;299:169-75.
43. Matucci A, Parronchi P, Vultaggio A et al. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004;59:1133-4.
44. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. A novel phenotype of nonsteroidal anti-inflammatory drug hypersensitivity. The high-risk patient. World Allergy Organ J 2009;2:17-9.
45. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7.
46. Slater EE, Merrill DD, Guess HA et al. Clinical profile of angioedema associated with angiotensin convertingenzyme inhibition. JAMA 1988;260:967-70.
47. Inomata N. [Diagnosis and treatment for urticaria.] [Jpn J Dermatol] 2008;118:2383-96 (in Japanese).
48. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 1997;278:232-3.
49. Gabb GM, Ryan P, Wing LM, Hutchinson KA. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996;26:777-82.
50. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
51. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:608-9.
52. Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005;165:1637-42.
53. Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509.
54. Abbosh J, Anderson JA, Levine AB, Kupin WL. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 1999;82:473-6.
55. Byrne TJ, Douglas DD, Landis ME, Heppell JP. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000;75:1201-4.
56. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffré D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999;44:21-5.
57. Niwa M, Nagasaka K, Takasu A et al. [Angioedema due to enalapril accompanied by upper respiratory obstruction]. Naika 1994;73:954-7 (in Japanese).
58. Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth 2006;53:994-1003.
59. Bas M, Hoffmann TK, Kojda G. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006;14:170-5.
60. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7.
61. Byrd JB, Touzin K, Sile S et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008;51:141-7.
62. Sigler C, Annis K, Cooper K, Haber H, Van deCarr S. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensinconverting enzyme inhibitor. Arch Dermatol 1997;133:972-5.
63. Blais C Jr, Rouleau JL, Brown NJ et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999;43:293-302.
64. Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides 2000;34:314-22.
65. Russell JS, Chi H, Lantry LE, Stephens RE, Ward PE. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides 1996;17:1397-403.
66. Duan QL, Nikpoor B, Dube MP et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005;77:617-26.
67. Sprinkle TJ, Stone AA, Venema RC, Denslow ND, Caldwell C, Ryan JW. Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25. Genomics 1998;50:114-6.
68. Shiber JR. Images in clinical medicine. Angioedema of the arytenoids. N Engl J Med 2005;353:e15.
69. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-15.
70. Thompson T, Frable MA. Drug-induced, life-threatening angioedema revisited. Laryngoscope 1993;103:10-2.
71. ONTARGET Investigators, Yusuf S, Teo KK et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
72. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007;98:57-63.
73. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005;111:315-20.
74. Hiyoshi H, Yayama K, Takano M, Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension 2004;43:1258-63.
75. Pfeffer MA, McMurray JJ, Velazquez EJ et al, and Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
76. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001;111:1729-31.
77. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitorinduced angioedema? Drug Saf 2002;25:73-6.
78. Anzaldua DA, Schmitz PG. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. Am J Kidney Dis 2008;51:532-3.
79. Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag 2011;7:337-44.
80. Fukutomi Y, Itagaki Y, Taniguchi M et al. Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 2011;127:531-3.
81. Chinuki Y, Kaneko S, Sakieda K, Murata S, Yoshida Y, Morita E. A case of wheat-dependent exercise-induced anaphylaxis sensitized with hydrolysed wheat protein in a soap. Contact Dermatitis 2011;65:55-7.
82. Inomata N. Wheat allergy. Curr Opin Allergy Clin Immunol 2009;9:238-43.